EU Says Pay-For-Delay Drug Settlements Still Down
European Union pay-for-delay settlements between brand pharmaceutical companies and their generic competitors to restrict generic entry into the market "have stabilized at a low level," European Commission antitrust regulators concluded in a...To view the full article, register now.
Already a subscriber? Click here to view full article